XML 21 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2017 $ 6 $ 472,552 $ (766) $ (446,375) $ 25,417
Balance (in shares) at Dec. 31, 2017 54,040,000        
Issuance of common stock upon exercise of stock options   13,331     13,331
Issuance of common stock upon exercise of stock options (in shares) 1,967,000        
Issuance of common stock under employee stock purchase plan ("ESPP")   3,617     3,617
Issuance of common stock under employee stock purchase plan ("ESPP") (in shares) 391,000        
Issuance of common stock upon exercise of warrants   6,762     6,762
Issuance of common stock upon exercise of warrants (in shares) 333,000        
Issuance of common stock for offering $ 1 96,776     96,777
Issuance of common stock for offering (in shares) 5,175,000        
Vesting of restricted stock (in shares) 177,000        
Stock based compensation   14,198     14,198
Unrealized gain on available-for-sale securities     214   214
Net loss       (128,154) (128,154)
Balance at Dec. 31, 2018 $ 7 607,236 (552) (574,529) 32,162
Balance (in shares) at Dec. 31, 2018 62,083,000        
Issuance of common stock upon exercise of stock options   13,041     13,041
Issuance of common stock upon exercise of stock options (in shares) 2,464,000        
Issuance of common stock under employee stock purchase plan ("ESPP")   4,323     4,323
Issuance of common stock under employee stock purchase plan ("ESPP") (in shares) 268,000        
Issuance of common stock for offering $ 1 323,409     323,410
Issuance of common stock for offering (in shares) 12,624,000        
Issuance of common stock to Orbimed   507     507
Issuance of common stock to Orbimed (in shares) 25,000        
Vesting of restricted stock (in shares) 541,000        
Stock based compensation   28,624     28,624
Unrealized gain on available-for-sale securities     1,471   1,471
Cumulative-effect adjustment upon adoption   (185)   185  
Net loss       (124,827) (124,827)
Balance at Dec. 31, 2019 $ 8 976,955 919 (699,171) $ 278,711
Balance (in shares) at Dec. 31, 2019 78,005,000       78,005,000
Issuance of common stock upon exercise of stock options   23,524     $ 23,524
Issuance of common stock upon exercise of stock options (in shares) 2,092,000        
Issuance of common stock under employee stock purchase plan ("ESPP")   7,114     7,114
Issuance of common stock under employee stock purchase plan ("ESPP") (in shares) 234,000        
Issuance of common stock for offering $ 1 270,649     270,650
Issuance of common stock for offering (in shares) 4,792,000        
Vesting of restricted stock (in shares) 1,100,000        
Stock based compensation   50,171     50,171
Unrealized gain on available-for-sale securities     3,340   3,340
Cumulative-effect adjustment upon adoption       (404) (404)
Equity component of Convertible Notes, net   82,873     82,873
Net loss       (229,743) (229,743)
Balance at Dec. 31, 2020 $ 9 $ 1,411,286 $ 4,259 $ (929,318) $ 486,236
Balance (in shares) at Dec. 31, 2020 86,223,000       86,223,000